Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
about
Idiotype vaccination for Non-Hodgkin lymphomaIdiotype vaccination for Non-Hodgkin lymphomaCancer immunotherapy: moving beyond current vaccinesEnhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cellsA novel proteoliposomal vaccine induces antitumor immunity against follicular lymphomaProgress and controversies in developing cancer vaccines.Lymphoma Immunotherapy: Current StatusApplications of next-generation sequencing to blood and marrow transplantationClinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesHigh-dimensional single-cell cancer biologyRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.Cancer immunotherapy via dendritic cellsAutologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Active idiotypic vaccination versus control immunotherapy for follicular lymphomaConverting tumor-specific markers into reporters of oncolytic virus infection.Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaGenetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphomaTargeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in miceTumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyUse of tumour-responsive T cells as cancer treatment.Tetanus toxoid-pulsed monocyte vaccination for augmentation of collateral vessel growthThe biology of human lymphoid malignancies revealed by gene expression profiling.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Pathogenic and Epiphenomenal Anti-DNA Antibodies in SLE.Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytesGeneration of dendritic cell-based vaccines for cancer therapy.CD8+ T-cell memory in tumor immunology and immunotherapy.Vaccination therapy for cutaneous T-cell lymphoma.New approaches in the immunotherapy of haematological malignancies.Controversies in clinical cancer dormancyCellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiences.Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphomaIRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.Some interfaces of dendritic cell biology.Against the self: dendritic cells versus cancer.
P2860
Q24186272-1346FE9A-4D04-4C14-B00E-8EC00FBFD18BQ24235281-F2F8012E-71DB-4961-91CA-5ED8AEFB962FQ24548229-78EA91E4-07F9-4B98-B267-9051A8C2609EQ24658494-3355F695-1471-4E09-9C1D-09A91E7C3F30Q24681501-83DEFE1C-B968-48BD-9E7A-48599188742DQ24810256-0A088564-BAFF-487E-A817-44E03303DD8FQ26782902-F6B585D9-E68B-460E-B883-E4B57F729189Q26852890-62B2CAE2-FDC2-4358-9FE8-86EBEFE0E06BQ26864603-800FBC58-C879-4E2F-9C1F-EAB4D57B8079Q27021173-B26C1F48-82BA-4120-B0EB-DBE87491190FQ27686800-A6B1BABA-F6E5-4B83-ADE6-1FE5BFB54E5FQ27693252-8D007C00-2BE8-4EAC-A0C7-F3AE8F5106B8Q29615444-662FD441-40E7-4C2D-87D7-9C4C0082ABD6Q31157425-F0F1782E-3FB4-4024-981A-2D0780E8EA59Q33261122-8818B784-AB89-4BAC-9B20-3427070EFF69Q33386521-07F43BB6-21CD-4DE6-936A-2663DEE71DD3Q33691505-330BF58D-606F-4A25-96EA-518F707968B3Q33713865-D6944394-DD55-4000-A450-242AA7B9501DQ33732491-D9CBEBBB-576C-4880-8A7D-38F0BDBF938CQ33814247-D6F6B23B-BD4B-4D38-BB62-7D9462256024Q33989839-910AD534-8285-4920-B615-52480662236EQ34038839-77C8FC0E-82DC-4791-AA44-6C2705B89D52Q34194680-AA984070-979F-4925-A8C1-F1C46C054703Q34285656-596C7C2E-8529-4E77-8D5F-1B7048073AB3Q34297077-BBEA29BB-9F96-40DE-8998-546F3847CD19Q34313320-A2390B67-54BB-42D1-87E9-8F99E9158AC2Q34328457-11608D2C-DC2D-4DE9-8B2D-CECD51025859Q34340333-39A24AFC-5453-4E44-AACE-738940199136Q34496957-A6CD00B1-EEEF-4829-8E4E-90BBE24F8CDBQ34658123-47957F12-0B95-47D9-BE8B-1C3E911C21E8Q34708252-D552E10C-E9B4-41CC-A2A8-17D3052E0DE1Q34768139-54BFFD7B-4436-4D8A-8ED4-959F5ECD85C5Q35015875-43E5C0BC-58F0-4464-9A61-4404F8125BD0Q35106657-5ABC2CE6-9A99-44A3-BB1D-37C08EC8F89FQ35134139-0EFF5BCE-840F-4E57-928E-EB19AE983E3EQ35137164-E59AB0F1-D964-48EA-A2FA-0C491A86E299Q35154940-5BAC1D68-3D5A-4777-BFA8-C0F3A14F9415Q35156105-136F0DB3-EDCD-4A7F-B446-98FC30FF69F1Q35219290-AD8A18FC-5A31-4FF7-87DE-624B61DA0228Q35219334-DF804DC5-4B95-4179-8819-6FEE76AE5B9D
P2860
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Idiotype-pulsed dendritic cell ...... mune responses in 35 patients.
@en
Idiotype-pulsed dendritic cell ...... mune responses in 35 patients.
@nl
type
label
Idiotype-pulsed dendritic cell ...... mune responses in 35 patients.
@en
Idiotype-pulsed dendritic cell ...... mune responses in 35 patients.
@nl
prefLabel
Idiotype-pulsed dendritic cell ...... mune responses in 35 patients.
@en
Idiotype-pulsed dendritic cell ...... mune responses in 35 patients.
@nl
P2093
P356
P1433
P1476
Idiotype-pulsed dendritic cell ...... mune responses in 35 patients.
@en
P2093
Adrienne van Beckhoven
Behnaz Taidi
Claudia Benike
Clemens B Caspar
Craig Y Okada
Debra K Czerwinski
Edgar G Engleman
Frank J Hsu
John M Timmerman
Ranjani Rajapaksa
P304
P356
10.1182/BLOOD.V99.5.1517
P407
P577
2002-03-01T00:00:00Z